Imperial's work on a self-amplifying RNA vaccine continues
Imperial and its partners are closing VacEquity Global Health (VGH).
The company was founded in May 2020 to support fast-track development and global distribution of Imperial's COVID-19 vaccine candidate. At the time, there were no proven COVID vaccines. As other first generation COVID vaccines now roll out, and Imperial's vaccine team refocus on new variants and developing self-amplifying RNA technology for other conditions, VGH is no longer needed.
Imperial and its partners, including VaxEquity (VXT), will continue to seek to develop self-amplifying RNA vaccines that can ultimately be distributed to the widest possible global population at low cost, including for low- and middle-income countries.
Imperial's COVID vaccine research continues, including via existing clinical trials and the development of self-amplifying RNA technology to take on new variants.
VaxEquity continues to support the development of self-amplifying RNA technology for other disease areas.
Article text (excluding photos or graphics) © Imperial College London.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.
